Cannara Biotech (STU:8CB0) Debt-to-Revenue : 0.46 (As of Feb. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cannara Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2025 was €9.93 Mil. Cannara Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2025 was €22.88 Mil. Cannara Biotech's annualized Revenue for the quarter that ended in Feb. 2025 was €71.40 Mil. Cannara Biotech's annualized Debt-to-Revenue for the quarter that ended in Feb. 2025 was 0.46.

Cannara Biotech Debt-to-Revenue Historical Data

The historical data trend for Cannara Biotech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Debt-to-Revenue Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Debt-to-Revenue

Get a 7-Day Free Trial

5.07

1.23

1.35

0.80

0.59

Cannara Biotech Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Debt-to-Revenue	Get a 7-Day Free Trial															0.63	0.63	0.52	0.49	0.46

Competitive Comparison of Cannara Biotech's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannara Biotech's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Cannara Biotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cannara Biotech's Debt-to-Revenue for the fiscal year that ended in Aug. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(6.313	+	25.787)	/	54.299
	=	0.59

Cannara Biotech's annualized Debt-to-Revenue for the quarter that ended in Feb. 2025 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(9.925	+	22.879)	/	71.396
	=	0.46

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Feb. 2025) Revenue data.

Cannara Biotech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (STU:8CB0) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

LOVFF:USA LOVE:Canada

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Cannara Biotech Headlines

No Headlines